Chiron bought for billions

News

Chiron Corporation has entered into a merger agreement with Novartis under which Novartis will acquire all of the shares of Chiron that it does not currently own for $5.1 billion.

has entered into a merger agreement with

under which Novartis will acquire all of the shares of Chiron that it does not currently own.

Novartis will acquire approximately 113 million Chiron shares, or 58 percent of all Chiron shares, for $45.00 per Chiron share, or a total of approximately $5.1 billion in cash.

"Chiron has recently made tremendous strides, including returning to the US influenza vaccine market, building a compelling oncology pipeline and extending our growth in the Blood Testing business,” said Howard Pien, chief executive officer of Chiron. "We believe that Chiron's businesses will have significant growth opportunities as part of Novartis, which will enable us to continue to bring innovative products to patients."

According to a statement, Chiron's global Vaccines business, the fifth largest in the world and one of the largest suppliers of influenza vaccines, provides Novartis with entry into an increasingly attractive segment of the healthcare market and a promising source of growth.

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox

Register
Or continue by

Signing in with your registered email address